Patient‐reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma
To assess the impact of adding trastuzumab on patient-reported outcomes (PROs) in localized HER2+ esophageal adenocarcinoma.
Phase 3 trial design
Inclusion of patients with HER2 overexpressing esophageal adenocarcinoma
Comparison of PROs between groups receiving and not receiving trastuzumab
No improvement in patient-reported outcomes with the addition of trastuzumab to combined radiation therapy.
Abstract
The addition of trastuzumab to CRT for localized HER2+ EAC did not improve PROs.
AIに質問
Like
Bookmark
Share
View Full Paper
AIに質問
Like
Bookmark
Share
View Full Paper
Patient‐reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma | Synapse